BioSight
Companies
MediWound Ltd. logo

MDWD

NASDAQYAVNE, L3
MediWound Ltd.

MediWound Ltd. is a commercial-stage biopharmaceutical company focused on wound care and dermatology, with approved products including NexoBrid, a bromelain-based enzymatic debridement agent for severe burns. The company manufactures its proprietary bromelain intermediate through a supply agreement with Challenge Bioproducts Corporation and distributes products through partnerships including an agreement with Mölnlycke. MediWound operates as an Israeli resident company listed on recognized stock exchanges and markets its therapeutic offerings to address burn wound management and related dermatological conditions.

Price history not yet available for MDWD.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar